Neidle_Quadruplex-binding compounds - A novel anticancer strategy

Available For: Exclusive Licensing

Summary

We have a first-in-class optimized small-molecule drug candidate ready for IND enabling studies with superior efficacy and activity against pancreatic cancer compared to existing agents, together with a distinct mechanism of action.

The Technology and its Advantages

The development of a malignancy within the pancreas is a multistep process, several key oncogenes must be activated and tumor suppressor genes inactivated in order for cells to proliferate indiscriminately. We have developed a lead compound through rounds of chemistry optimisation which shows efficacy in several animal models tested. The molecule presents a novel mechanism of action where it targets G-quadruplex structures present on multiple gene promoters, allowing us to control the expression of several oncogenes, rendering the development of drug resistance unlikely.

Market Opportunity

Improvements in prevention, detection and treatment have happened over recent years, however there is still a large unmet need in a number of hard to treat cancers, examples including pancreatic cancer, prostate cancer, gastro-intestinal cancer and non-small-cell lung cancer.

Intellectual Property Status

Patent portfolio filed worldwide.

Further Information

Please contact, Rachel Colman |T: +44 (0)20 7679 9000 | E: r.colman@uclb.com

The technology referred to herein is experimental in nature and UCL Business Ltd makes no representations and gives no warranties of any kind, either express or implied, in relation to the technology and, in particular but without limiting the foregoing, UCL Business Ltd gives no express or implied warranties of merchantability, satisfactory quality or fitness for a particular purpose.